Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: The EMPA-KIDNEY trial. American Heart Association.
Lua i Stíl Chicago (17ú heag.)Preiss, D., W. Herrington, agus R. Haynes. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.
Lua MLA (9ú heag.)Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: The EMPA-KIDNEY Trial. American Heart Association, 2022.
Rabhadh: Seans nach mbeach na luanna seo go hiomlán cruinn i ngach uile chás.